Ginkgo Bioworks (NYSE:DNA) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Ginkgo Bioworks (NYSE:DNA) posted its quarterly earnings data on Thursday. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.04, FiscalAI reports. Ginkgo Bioworks had a negative net margin of 249.20% and a negative return on equity of 54.95%. The company had revenue of $27.71 million during the quarter, compared to the consensus estimate of $21.50 million.

Here are the key takeaways from Ginkgo Bioworks’ conference call:

• Ginkgo announced its first autonomous-lab hardware sale to a pharma company, Novo Nordisk, and wins involving universities, ARPA-H and the NSF. Management said systems typically take six to 12 months to install, so customer wins may take time to translate into revenue.
• Cloud Lab services added 20 new customer logos in the quarter, and Ginkgo highlighted demand for specialized data services, including its antibody developability consortium and work with frontier AI labs. These opportunities are management’s view of potential growth areas; the call did not quantify their revenue contribution.
• Q3 revenue was $28 million, down 6% year over year; revenue for the first nine months fell 37% (about 32% excluding a prior-year non-cash item). Q3 revenue rose sequentially partly because of a catch-up on a modified long-term contract.
• Cost reductions improved Q3 results: R&D expense fell 48%, G&A fell 32%, net loss from continuing operations narrowed 44% to $41 million, and adjusted EBITDA improved 58% to negative $22 million. Management reaffirmed full-year 2026 cash-burn guidance of $125 million to $150 million.
• Ginkgo ended the quarter with $285 million in cash and marketable securities, no bank debt, and $86 million in restricted cash. Q3 cash burn was $27 million, while adjusted EBITDA included about $14 million of quarterly costs for unused leased space.

Ginkgo Bioworks Stock Up 13.0%

Shares of NYSE DNA traded up $1.30 during mid-day trading on Friday, hitting $11.26. The stock had a trading volume of 3,035,139 shares, compared to its average volume of 2,566,626. The business has a 50 day moving average price of $9.90 and a two-hundred day moving average price of $8.62. Ginkgo Bioworks has a 1 year low of $5.37 and a 1 year high of $18.22.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. BTIG Research reissued a “sell” rating and set a $5.00 price objective on shares of Ginkgo Bioworks in a report on Friday, September 4th. Wall Street Zen raised shares of Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. TD Cowen upped their price objective on shares of Ginkgo Bioworks from $9.00 to $11.00 and gave the company a “hold” rating in a research note on Tuesday, October 13th. Zacks Research raised shares of Ginkgo Bioworks to a “hold” rating in a report on Monday, August 17th. Finally, Oppenheimer set a $5.00 target price on shares of Ginkgo Bioworks in a research report on Wednesday, September 9th. Two equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Ginkgo Bioworks currently has an average rating of “Reduce” and a consensus target price of $7.00.

Insider Buying and Selling at Ginkgo Bioworks

In other news, insider Reshma P. Shetty sold 18,803 shares of the company’s stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $10.14, for a total transaction of $190,662.42. Following the completion of the transaction, the insider directly owned 356,329 shares of the company’s stock, valued at approximately $3,613,176.06. This represents a 5.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven P. Coen sold 2,403 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $15.00, for a total transaction of $36,045.00. Following the transaction, the insider directly owned 49,448 shares of the company’s stock, valued at approximately $741,720. This trade represents a 4.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 136,525 shares of company stock worth $1,379,699 over the last ninety days. 12.69% of the stock is owned by company insiders.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks is a biotechnology company that develops and deploys biological systems for commercial and industrial applications. Its platform is designed to help customers program cells to produce a wide range of products, including pharmaceuticals, food ingredients, agricultural inputs, specialty chemicals and materials. The company combines biological engineering, automation, software and data science to design, build and test engineered organisms.

Ginkgo provides services through its cell-programming platform and biological engineering foundry, supporting activities such as genetic design, strain construction, laboratory testing and process development.